BIOCHEMICAL SOCIETY TRANSACTIONS involved incubations for a standard period of 32 h. Data in Fig. l ( b ) indicate that the production rate of IGF-1 was sensitive to the amount of glucose and amino acids in the medium. Altering the concentration of glucose plus amino acids, or glucose alone (10 to 130% and 25 to 200%, respectively of the standard concentration) resulted in exponential changes in IGF-1 production. When amino acid concentration was varied independently of glucose, between the range 15 to 100% similar responses were observed, but above 100% production was reduced, probably because of pH changes in the medium.
BIOCHEMICAL SOCIETY TRANSACTIONS involved incubations for a standard period of 32 h. Data in Fig. l ( b ) indicate that the production rate of IGF-1 was sensitive to the amount of glucose and amino acids in the medium. Altering the concentration of glucose plus amino acids, or glucose alone (10 to 130% and 25 to 200%, respectively of the standard concentration) resulted in exponential changes in IGF-1 production. When amino acid concentration was varied independently of glucose, between the range 15 to 100% similar responses were observed, but above 100% production was reduced, probably because of pH changes in the medium.
Although previous reports indicate that GH increases IGF-1 production [3] and IGF-1 mRNA concentrations [4] in rat hepatocytes as well as plasma IGF-1 concentrations in growing sheep [S], and pigs [ 6 ] , the present experiment showed no difference in IGF-1 production in the presence of 0, 5 and 200 pg/l rbGH. This finding is in agreement with earlier observations of Postel-Vinay and colleagues [7] .
Based on these observations it would appear that IGF-I production by rat liver cells is directly influenced by nutrient availability but is not responsive to GH.
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Several groups of workers have investigated the relationship between drug metabolism in isolated hepatocytes and that in vivo [l-31. There is a growing interest in using isolated hepatocytes to predict the intrinsic metabolic clearance of drugs in vivo [4] . Conventional kinetic studies with hepatocytes can reveal the apparent maximum rate of metabolism ( V ) and the substrate (drug) concentration required to give half the apparent maximum rate (K,,,). Under first-order conditions V and K , can be related to intrinsic clearance (CIln,,) of substrate by the relationship Clint. = V/K,.
Intrinsic clearance may also be determined in vivo by pharmacokinetic analysis of circulating drug concentration.
The relationship CIP,a,ma = CIKena! + CIHepallc allows the calculation of hepatic clearance which, together with the free fraction of drug in plasma, can provide data on intrinsic clearance in vivo. In this study we compare the intrinsic clearance calculated from apparent V and K , values in isolated hepatocytes with that from pharmacokinetic analysis for the H,-receptor antagonist loxtidine hemisuccinate, a compound with a low hepatic extraction ratio.
In laboratory animals 151 and man loxtidine undergoes metabolism by several routes and shows significant species differences. In rat the major route of metabolism is Ndealkylation, but in dog loxtidine is extensively conjugated with glucuronic acid. In man loxtidine is excreted predominantly unchanged although a minor phase I metabolite was observed. We have investigated the metabolism of loxtidine in hepatocytes isolated from rat, dog and man and have observed the same pattern of metabolites as in vivo for each species. Conventional kinetic analysis was used to calculate apparent K,, and V which were then used to calculate intrinsic clearance. Intrinsic clearance was also calculated from pharmacokinetic data in vivo obtained from rat. dog and healthy volunteers.
Hepatocytes were isolated using a modified three stage collagenase perfusion [ 6 ] from rat liver, beagle dog and human wedge biopsy samples. Viabilities from all species were in excess of 87%. Isolated hepatocytes were suspended in Williams Medium E containing glutamine (approximately 2 X loh cells/ml). [I4C]Loxtidine (0.06 MBq/mg) (1-100 ,UM) was incubated with rat, dog and human hepatocyte suspensions at 37°C for 3 h under a water saturated atmosphere of oxygen/carbon dioxide (95%: v/v). Samples were withdrawn at various times and the reaction was stopped by rapid freezing in liquid nitrogen. Metabolites and substrate were In vivo R a t ( n = 3 ) Dog ( n = 2) M a n ( n = 5 ) 635th MEETING, ABERDEEN analysed by t.1.c. Radioactive areas on thin layer plates were recordcd and integrated by use of a linear analyser. Intrinsic clearance values were calculated using values of 120 x 10" hepatocytes/g for rat and human liver [7. 81 and 2 4 0~ 10" hepatocytes/g for dog liver. Pharmacokinetic parameters of loxtidinc were determined in rat ( ri = 3) and dog ( ti = 2 ) following intravenous administration at a dose level of 5 mg base/kg, and in human voluntcers ( t i = 5 ) at doses ranging from 0.025 to 0.5 mg base/kg. Loxtidine concentrations in plasma and urine were measured by specific radioimmunoassay 19 I and h.p.1.c.
Apparent kinetic constants together with intrinsic clearance values obtained from rat, dog and human hepatocytes are shown in Table I . Data for the metabolic intrinsic clearance of loxtidine irr viiro and iri vitw were in the same rank order rat > dog> man. Our studies also show that thc intrinsic clearance of loxtidine determined iri vitro were similar to those calculated iri ~i~n .
These preliminary studies indicate that the determination of metabolic clearance in isolated hepatocytes can provide useful information about the rate and extent o f metabolism of a drug irr vivo.
We thank I>r P. C'arey lor the analy\iz o f loxtidinc in human urine.
Ranitidine is an HI-receptor antagonist used in the treatment o f diseases associated with gastric acid hypersecretion. We have investigated the enzymology of the formation of ranitidine N-oxide. S-oxide and N-desmethylranitidine in isolated hepatocytes from dog. Specifically the study was designed to distinguish the contributions of cytochrome 1'-450 (1'-450) and flavin-containing monooxygenase ( F M O ) by the use of inhibitors. SKF 525-A and N-benzylimidazole (BZI) inhibit various forms of 1'-450 whereas methimazole (MMI) and thiourea ( T h U ) are alternative substrates for FMO. A s reduced glutathione (GSH) prevents the depletion of 1'-450 by MMI metabolites [ I. 21 . the effects of GSH on MMI and ThU-mediated inhibition of ranitidine metabolism were also examined.
Beagle dogs had been the subject of pharmacological studies with candidate drugs and had received anaesthesia. Hepatocytes were isolated from end of lobe biopsies using a modified three stage collagenase perfusion [ 31 and were maintained as a suspension in Williams Medium E containing glutamine (WME: no phenol red) at a concentration of 2 x 10" viable cells per ml under a water-saturated atmosphere of 5% C0,:95°/o 0,. Initial viability was typically 90% as indicated by exclusion of Trypan Blue and was not compromised by substrate or inhibitor addition.
Inhibitors were dissolved in W M E and used to generate dose-response curves between the concentrations indicated. Experiments were initiated by addition of ranitidine hydrochloride to give a final concentration of 3 mM in 2 ml. Aliquots (200 p l ) removed at time zero and at intervals of up to 2 h were frozen in liquid nitrogen. Thawed samples were prepared for analysis by adding two volumes of acetone, Abbreviations used: 1'-450, cytochrome /'-4SO; FMO, flavincontaining monooxygenase; BZI, N-benzylimidazole; MMI, methimazole; ThU, thiourea; GSH, glutathione; WME, Williams Medium E. evaporating the supernatant under vacuum and redissolving the residue in one volume of methanol. Twenty microlitres o f this was then subjected to h.p.1.c. for quantification of the basic metabolites 14 I against standard curves generated from authenticated synthetic metabolites.
Dog hepatocytes transformed ranitidine t o its known metabolites. T h e metabolite profile observed iri vitro (ranitidine N-oxide + ranitidine S-oxide > desmcthylranitidine) corresponded with that previously observed in vivo 151. NOxidation o f ranitidine was inhibited by 5-500 ~M -M M I (41-96%) and T h U (27-97'Y0) in a dose-related fashion. In both cases the profile of inhibition was unaltered by the addition of GSH ( 1 mM). BZl(0.2-2.5 rnM),or SKF 525-A (5-250 p~) had no effect on the extent of N-oxidation showing that 1'-450 was not involved. S-Oxidation was inhibited by MMI (7-22%) and T h U (0-20%) but not by T h U in the presencc of GSH or by < 200 ~M -M M I with GSH. At 500 ~M -M M I , inhibition was unaltered by GSH. Inhibition by BZI was 49-5S0/0 and by SKF 525-A was 25-50% suggesting 1'-450 involvement. N-Demethylation was inhibited by MMI (17-54%) and T h U (4-43%). Inclusion of GSH removed inhibition at and below 5 0 ~M -M M I but did not alter the effects of 5 0 0 -p~ MMI. Although the role of GSH in preventing ThU-mediated inhibition of demethylation could not be clearly discerned, the lack of inhibition at low concentrations of MMI plus GSH indicates that F M O is not directly involved in demethylation. However. inhibition by BZ1 ( 12-4Sok1) and SKF 525-A ( 6 2 6 % ) does show P-450-mediated demethylation. In the absence of inhibitors, GSH did not affect ranitidine metabolism.
BZI has been suggested as an inhibitor of choice for differentiating [-'-450-from FMO-catalysed reactions [ 61. NOxidation of ranitidine was not altered by BZI or SKF 525-A but was almost entirely (07%) inhibited by co-incubation with alternative substrates for F M O (MMI and ThU), which suggests F M O alone was responsible for the N-oxide formed. Lack of inhibition by SKF 525-A indicates that this classical P-450 inhibitor was not interacting with F M O at the concentrations used. At least 50% of S-oxidation was susceptible to BZI indicating 1'-450 catalysis. Confirmatory inhibition was achieved by SKF 525-A (50%). A further 22%
